Drugs interactions for

  • 97 Major drug interactions (including ingredients like Abametapir, Aclidinium, Alfuzosin)
  • 652 Moderate drug interactions (including ingredients like Abatacept, Abiraterone, Acalabrutinib)
  • 255 Minor drug interactions (including ingredients like Abaloparatide, Aceclofenac, Acenocoumarol)
1004 interactions for
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
Abametapir
The serum concentration of Aripiprazole can be increased when it is combined with Abametapir.
Aclidinium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aclidinium.
Alfuzosin
Aripiprazole may increase the hypotensive activities of Alfuzosin.
Amiodarone
The metabolism of Aripiprazole can be decreased when combined with Amiodarone.
Amisulpride
Aripiprazole may increase the antipsychotic activities of Amisulpride.
Amitriptyline
Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Amoxapine
Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Aripiprazole lauroxil
Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.
Asenapine
Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.
Atazanavir
The metabolism of Aripiprazole can be decreased when combined with Atazanavir.
Axitinib
The metabolism of Axitinib can be decreased when combined with Aripiprazole.
Azelastine
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Cabazitaxel
The metabolism of Cabazitaxel can be decreased when combined with Aripiprazole.
Clarithromycin
The metabolism of Aripiprazole can be decreased when combined with Clarithromycin.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Aripiprazole.
Clonidine
The risk or severity of sedation can be increased when Clonidine is combined with Aripiprazole.
Conivaptan
The metabolism of Aripiprazole can be decreased when combined with Conivaptan.
Copanlisib
The metabolism of Copanlisib can be decreased when combined with Aripiprazole.
Curcumin
The metabolism of Aripiprazole can be decreased when combined with Curcumin.
Danazol
The metabolism of Aripiprazole can be decreased when combined with Danazol.
Darunavir
The metabolism of Aripiprazole can be decreased when combined with Darunavir.
Deutetrabenazine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Deutetrabenazine.
Dihydroergocristine
Dihydroergocristine may increase the vasoconstricting activities of Aripiprazole.
Doxepin
Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Efavirenz
The metabolism of Aripiprazole can be decreased when combined with Efavirenz.
Eluxadoline
The risk or severity of constipation can be increased when Aripiprazole is combined with Eluxadoline.
Elvitegravir
The metabolism of Aripiprazole can be decreased when combined with Elvitegravir.
Ergotamine
The metabolism of Aripiprazole can be decreased when combined with Ergotamine.
Ethanol
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Flecainide
The metabolism of Flecainide can be decreased when combined with Aripiprazole.
Gilteritinib
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gilteritinib.
Glycopyrronium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Glycopyrronium.
Hydroxyzine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Hydroxyzine.
Iloperidone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Iloperidone.
Indinavir
The metabolism of Aripiprazole can be decreased when combined with Indinavir.
Ipratropium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.
Isocarboxazid
The metabolism of Aripiprazole can be decreased when combined with Isocarboxazid.
Itraconazole
The metabolism of Aripiprazole can be decreased when combined with Itraconazole.
Ketoconazole
The metabolism of Aripiprazole can be decreased when combined with Ketoconazole.
Lefamulin
Lefamulin may increase the QTc-prolonging activities of Aripiprazole.
Levoketoconazole
The metabolism of Aripiprazole can be decreased when combined with Levoketoconazole.
Lonafarnib
The metabolism of Aripiprazole can be decreased when combined with Lonafarnib.
Lopinavir
The metabolism of Aripiprazole can be decreased when combined with Lopinavir.
Macimorelin
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Aripiprazole.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Aripiprazole.
Methimazole
The metabolism of Aripiprazole can be decreased when combined with Methimazole.
Methylene blue
Aripiprazole may increase the serotonergic activities of Methylene blue.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.
Midostaurin
The metabolism of Aripiprazole can be decreased when combined with Midostaurin.
Nefazodone
The metabolism of Aripiprazole can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Aripiprazole can be decreased when combined with Nelfinavir.
Nilotinib
The metabolism of Aripiprazole can be decreased when combined with Nilotinib.
Nortriptyline
Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Olanzapine
Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Aripiprazole is combined with Oliceridine.
Paliperidone
Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.
Phenelzine
The metabolism of Aripiprazole can be decreased when combined with Phenelzine.
Pitolisant
The therapeutic efficacy of Pitolisant can be decreased when used in combination with Aripiprazole.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Aripiprazole.
Ponesimod
The risk or severity of bradycardia can be increased when Ponesimod is combined with Aripiprazole.
Posaconazole
The metabolism of Aripiprazole can be decreased when combined with Posaconazole.
Pramlintide
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aripiprazole.
Procainamide
The metabolism of Procainamide can be decreased when combined with Aripiprazole.
Procaine
The metabolism of Aripiprazole can be decreased when combined with Procaine.
Procarbazine
The metabolism of Aripiprazole can be decreased when combined with Procarbazine.
Quetiapine
Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Rasagiline
The metabolism of Aripiprazole can be decreased when combined with Rasagiline.
Risperidone
Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Rizatriptan
The risk or severity of vasospastic reactions can be increased when Aripiprazole is combined with Rizatriptan.
Safinamide
The metabolism of Aripiprazole can be decreased when combined with Safinamide.
Saquinavir
The metabolism of Aripiprazole can be decreased when combined with Saquinavir.
Secretin human
The therapeutic efficacy of Secretin human can be decreased when used in combination with Aripiprazole.
Selegiline
The metabolism of Aripiprazole can be decreased when combined with Selegiline.
Silodosin
Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.
Sirolimus
The metabolism of Sirolimus can be decreased when combined with Aripiprazole.
Sodium oxybate
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sotalol
The metabolism of Sotalol can be decreased when combined with Aripiprazole.
Tamsulosin
Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Telithromycin
The metabolism of Aripiprazole can be decreased when combined with Telithromycin.
Temsirolimus
The metabolism of Temsirolimus can be decreased when combined with Aripiprazole.
Tetrabenazine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrabenazine.
Thalidomide
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Theophylline can be decreased when combined with Aripiprazole.
Tiotropium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiotropium.
Tipranavir
The metabolism of Aripiprazole can be decreased when combined with Tipranavir.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Aripiprazole.
Tranylcypromine
The metabolism of Aripiprazole can be decreased when combined with Tranylcypromine.
Trastuzumab emtansine
The metabolism of Trastuzumab emtansine can be decreased when combined with Aripiprazole.
Trazodone
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Aripiprazole.
Tretinoin
The risk or severity of elevated intracranial pressure can be increased when Aripiprazole is combined with Tretinoin.
Trifluoperazine
Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Trimipramine
Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Umeclidinium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Umeclidinium.
Vincristine
The metabolism of Vincristine can be decreased when combined with Aripiprazole.
Voriconazole
The metabolism of Aripiprazole can be decreased when combined with Voriconazole.
Ziprasidone
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ziprasidone.
Zolmitriptan
The risk or severity of vasospastic reactions can be increased when Aripiprazole is combined with Zolmitriptan.
Abatacept
The metabolism of Aripiprazole can be increased when combined with Abatacept.
Abiraterone
The metabolism of Aripiprazole can be decreased when combined with Abiraterone.
Acalabrutinib
The metabolism of Aripiprazole can be decreased when combined with Acalabrutinib.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.
Acebutolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Acebutolol.
Acetaminophen
The metabolism of Aripiprazole can be increased when combined with Acetaminophen.
Acetazolamide
The metabolism of Aripiprazole can be decreased when combined with Acetazolamide.
Adagrasib
The metabolism of Aripiprazole can be decreased when combined with Adagrasib.
Adalimumab
The metabolism of Aripiprazole can be increased when combined with Adalimumab.
Albuterol
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Aripiprazole.
Aldesleukin
The metabolism of Aripiprazole can be decreased when combined with Aldesleukin.
Alfentanil
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfentanil.
Aliskiren
The risk or severity of hypotension can be increased when Aripiprazole is combined with Aliskiren.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.
Alosetron
The risk or severity of CNS depression can be increased when Alosetron is combined with Aripiprazole.
Alpelisib
The metabolism of Aripiprazole can be increased when combined with Alpelisib.
Alprazolam
The risk or severity of CNS depression can be increased when Alprazolam is combined with Aripiprazole.
Amantadine
The therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.
Ambrisentan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Ambrisentan.
Amlodipine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Amlodipine.
Amobarbital
The metabolism of Aripiprazole can be increased when combined with Amobarbital.
Amphetamine
Amphetamine may decrease the sedative activities of Aripiprazole.
Anagrelide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Anagrelide.
Anakinra
The metabolism of Aripiprazole can be increased when combined with Anakinra.
Apalutamide
The serum concentration of Aripiprazole can be decreased when it is combined with Apalutamide.
Apomorphine
The risk or severity of adverse effects can be decreased when Apomorphine is combined with Aripiprazole.
Apremilast
The metabolism of Aripiprazole can be increased when combined with Apremilast.
Aprepitant
The metabolism of Aripiprazole can be decreased when combined with Aprepitant.
Aprocitentan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Aprocitentan.
Arformoterol
The therapeutic efficacy of Arformoterol can be decreased when used in combination with Aripiprazole.
Armodafinil
The metabolism of Aripiprazole can be increased when combined with Armodafinil.
Arsenic trioxide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Arsenic trioxide.
Artemether
The metabolism of Aripiprazole can be increased when combined with Artemether.
Articaine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Articaine.
Asunaprevir
The metabolism of Aripiprazole can be increased when combined with Asunaprevir.
Atenolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Atenolol.
Atracurium besylate
The risk or severity of CNS depression can be increased when Atracurium besylate is combined with Aripiprazole.
Avanafil
Aripiprazole may increase the hypotensive activities of Avanafil.
Azilsartan medoxomil
The risk or severity of hypotension can be increased when Aripiprazole is combined with Azilsartan medoxomil.
Beclomethasone dipropionate
The metabolism of Aripiprazole can be increased when combined with Beclomethasone dipropionate.
Bedaquiline
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Bedaquiline.
Benazepril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Benazepril.
Bendroflumethiazide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Bendroflumethiazide.
Benzatropine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzatropine.
Benzhydrocodone
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzhydrocodone.
Benzocaine
The risk or severity of CNS depression can be increased when Benzocaine is combined with Aripiprazole.
Benzphetamine
Benzphetamine may decrease the sedative activities of Aripiprazole.
Benzyl alcohol
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Benzyl alcohol.
Benzylpenicilloyl polylysine
Aripiprazole may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Berotralstat
The metabolism of Aripiprazole can be decreased when combined with Berotralstat.
Betamethasone
The metabolism of Aripiprazole can be increased when combined with Betamethasone.
Betaxolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Betaxolol.
Bexagliflozin
The therapeutic efficacy of Bexagliflozin can be decreased when used in combination with Aripiprazole.
Bexarotene
The metabolism of Aripiprazole can be increased when combined with Bexarotene.
Bicalutamide
The metabolism of Aripiprazole can be decreased when combined with Bicalutamide.
Bimekizumab
The metabolism of Aripiprazole can be increased when combined with Bimekizumab.
Bisoprolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Bisoprolol.
Bosentan
The metabolism of Aripiprazole can be increased when combined with Bosentan.
Bosutinib
The metabolism of Aripiprazole can be decreased when combined with Bosutinib.
Botulinum toxin type B
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum toxin type B.
Brentuximab vedotin
The metabolism of Aripiprazole can be decreased when combined with Brentuximab vedotin.
Bretylium
The risk or severity of hypotension can be increased when Aripiprazole is combined with Bretylium.
Brexanolone
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Brexanolone.
Brexpiprazole
The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Brexpiprazole.
Brigatinib
The metabolism of Aripiprazole can be increased when combined with Brigatinib.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Brivaracetam
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Brivaracetam.
Bromocriptine
The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Aripiprazole.
Brompheniramine
The risk or severity of CNS depression can be increased when Brompheniramine is combined with Aripiprazole.
Budesonide
The metabolism of Aripiprazole can be increased when combined with Budesonide.
Bupivacaine
The risk or severity of CNS depression can be increased when Bupivacaine is combined with Aripiprazole.
Buprenorphine
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The serum concentration of Aripiprazole can be increased when it is combined with Bupropion.
Buspirone
The risk or severity of CNS depression can be increased when Buspirone is combined with Aripiprazole.
Butalbital
The metabolism of Aripiprazole can be increased when combined with Butalbital.
Butorphanol
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Butorphanol.
Cabergoline
The risk or severity of adverse effects can be decreased when Cabergoline is combined with Aripiprazole.
Calcitriol
The metabolism of Aripiprazole can be increased when combined with Calcitriol.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.
Canakinumab
The metabolism of Aripiprazole can be increased when combined with Canakinumab.
Candesartan cilexetil
The risk or severity of hypotension can be increased when Aripiprazole is combined with Candesartan cilexetil.
Cannabidiol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Aripiprazole.
Capsaicin
The metabolism of Aripiprazole can be decreased when combined with Capsaicin.
Captopril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Captopril.
Carbamazepine
The metabolism of Aripiprazole can be increased when combined with Carbamazepine.
Carbidopa
The therapeutic efficacy of Carbidopa can be decreased when used in combination with Aripiprazole.
Carbinoxamine
The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Aripiprazole.
Cariprazine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Cariprazine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Aripiprazole.
Carvedilol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Carvedilol.
Celecoxib
The metabolism of Aripiprazole can be decreased when combined with Celecoxib.
Cenobamate
The serum concentration of Aripiprazole can be decreased when it is combined with Cenobamate.
Ceritinib
The metabolism of Aripiprazole can be decreased when combined with Ceritinib.
Certolizumab pegol
The metabolism of Aripiprazole can be increased when combined with Certolizumab pegol.
Cetirizine
The risk or severity of CNS depression can be increased when Cetirizine is combined with Aripiprazole.
Chloramphenicol
The metabolism of Aripiprazole can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Aripiprazole.
Chloroprocaine
The risk or severity of CNS depression can be increased when Chloroprocaine is combined with Aripiprazole.
Chloroquine
The metabolism of Aripiprazole can be decreased when combined with Chloroquine.
Chlorothiazide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Chlorothiazide.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Aripiprazole.
Chlorpromazine
The metabolism of Aripiprazole can be increased when combined with Chlorpromazine.
Chlorthalidone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Chlorthalidone.
Chlorzoxazone
The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Aripiprazole.
Cholecalciferol
The metabolism of Aripiprazole can be decreased when combined with Cholecalciferol.
Cimetidine
The metabolism of Aripiprazole can be decreased when combined with Cimetidine.
Cinacalcet
The serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.
Cinchocaine
The risk or severity of CNS depression can be increased when Cinchocaine is combined with Aripiprazole.
Ciprofloxacin
The metabolism of Aripiprazole can be decreased when combined with Ciprofloxacin.
Cisatracurium
The risk or severity of CNS depression can be increased when Cisatracurium is combined with Aripiprazole.
Citalopram
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Citalopram.
Clemastine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Clemastine.
Clevidipine
The metabolism of Aripiprazole can be increased when combined with Clevidipine.
Clidinium
The risk or severity of CNS depression can be increased when Clidinium is combined with Aripiprazole.
Clobazam
The serum concentration of Aripiprazole can be increased when it is combined with Clobazam.
Clobetasol propionate
The metabolism of Aripiprazole can be increased when combined with Clobetasol propionate.
Clonazepam
The risk or severity of CNS depression can be increased when Clonazepam is combined with Aripiprazole.
Clorazepic acid
The risk or severity of CNS depression can be increased when Clorazepic acid is combined with Aripiprazole.
Clozapine
The risk or severity of reduced gastrointestinal motility can be increased when Aripiprazole is combined with Clozapine.
Cobicistat
The metabolism of Aripiprazole can be decreased when combined with Cobicistat.
Cocaine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Codeine.
Corticotropin
The metabolism of Aripiprazole can be increased when combined with Corticotropin.
Cortisone acetate
The metabolism of Aripiprazole can be increased when combined with Cortisone acetate.
Crizotinib
The metabolism of Aripiprazole can be decreased when combined with Crizotinib.
Cyclobenzaprine
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Aripiprazole.
Cyclophosphamide
The metabolism of Aripiprazole can be increased when combined with Cyclophosphamide.
Cyclosporine
The metabolism of Aripiprazole can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Aripiprazole.
Dabrafenib
The serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.
Dacomitinib
The serum concentration of Aripiprazole can be increased when it is combined with Dacomitinib.
Dalfopristin
The metabolism of Aripiprazole can be decreased when combined with Dalfopristin.
Dantrolene
The risk or severity of CNS depression can be increased when Dantrolene is combined with Aripiprazole.
Dapagliflozin
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Aripiprazole.
Darifenacin
The metabolism of Aripiprazole can be decreased when combined with Darifenacin.
Dasatinib
The metabolism of Aripiprazole can be decreased when combined with Dasatinib.
Dasiglucagon
The risk or severity of hypotension can be increased when Aripiprazole is combined with Dasiglucagon.
Daunorubicin
The metabolism of Aripiprazole can be decreased when combined with Daunorubicin.
Deferasirox
The metabolism of Aripiprazole can be increased when combined with Deferasirox.
Delafloxacin
The metabolism of Aripiprazole can be increased when combined with Delafloxacin.
Desflurane
The risk or severity of CNS depression can be increased when Desflurane is combined with Aripiprazole.
Desipramine
The metabolism of Aripiprazole can be decreased when combined with Desipramine.
Desloratadine
The risk or severity of CNS depression can be increased when Desloratadine is combined with Aripiprazole.
Desvenlafaxine
The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Aripiprazole.
Dexamethasone
The metabolism of Aripiprazole can be increased when combined with Dexamethasone.
Dexamethasone acetate
The metabolism of Aripiprazole can be increased when combined with Dexamethasone acetate.
Dexbrompheniramine
The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Aripiprazole.
Dexchlorpheniramine maleate
The metabolism of Aripiprazole can be decreased when combined with Dexchlorpheniramine maleate.
Dexmedetomidine
The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Aripiprazole.
Dexmethylphenidate
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexmethylphenidate.
Dextroamphetamine
Dextroamphetamine may decrease the sedative activities of Aripiprazole.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aripiprazole.
Dextropropoxyphene
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextropropoxyphene.
Diazepam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Diazepam.
Diazoxide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Diazoxide.
Dicloxacillin
The metabolism of Aripiprazole can be increased when combined with Dicloxacillin.
Diethylpropion
Diethylpropion may decrease the sedative activities of Aripiprazole.
Difenoxin
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.
Dihydroergocornine
The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Dihydroergocornine.
Dihydroergotamine
The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Aripiprazole.
Diltiazem
The metabolism of Aripiprazole can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Aripiprazole.
Dimethyl sulfoxide
The metabolism of Aripiprazole can be decreased when combined with Dimethyl sulfoxide.
Diphenhydramine
The risk or severity of CNS depression can be increased when Diphenhydramine is combined with Aripiprazole.
Diphenoxylate
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Diphenoxylate.
Dipyridamole
The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Aripiprazole.
Disopyramide
The therapeutic efficacy of Disopyramide can be decreased when used in combination with Aripiprazole.
DL-Methylephedrine
The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Aripiprazole.
Dobutamine
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Aripiprazole.
Docetaxel
The metabolism of Aripiprazole can be decreased when combined with Docetaxel.
Dofetilide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dofetilide.
Dolasetron
The risk or severity of CNS depression can be increased when Dolasetron is combined with Aripiprazole.
Donepezil
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Donepezil.
Doxazosin
The risk or severity of hypotension can be increased when Aripiprazole is combined with Doxazosin.
Doxorubicin
The metabolism of Aripiprazole can be decreased when combined with Doxorubicin.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Dronabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Droxidopa
Aripiprazole may increase the hypertensive activities of Droxidopa.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.
Duloxetine
The metabolism of Aripiprazole can be decreased when combined with Duloxetine.
Dyclonine
The risk or severity of CNS depression can be increased when Dyclonine is combined with Aripiprazole.
Elafibranor
The metabolism of Aripiprazole can be increased when combined with Elafibranor.
Elbasvir
The metabolism of Aripiprazole can be decreased when combined with Elbasvir.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Aripiprazole.
Eliglustat
The metabolism of Aripiprazole can be decreased when combined with Eliglustat.
Emapalumab
The metabolism of Aripiprazole can be increased when combined with Emapalumab.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.
Enalapril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Enalapril.
Enalaprilat
The risk or severity of hypotension can be increased when Aripiprazole is combined with Enalaprilat.
Enasidenib
The metabolism of Aripiprazole can be increased when combined with Enasidenib.
Encorafenib
The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Aripiprazole.
Entacapone
The therapeutic efficacy of Entacapone can be decreased when used in combination with Aripiprazole.
Entrectinib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entrectinib.
Enzalutamide
The serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Aripiprazole can be increased when it is combined with Epcoritamab.
Ephedrine
The therapeutic efficacy of Ephedrine can be decreased when used in combination with Aripiprazole.
Epicriptine
The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Epicriptine.
Epinastine
The risk or severity of CNS depression can be increased when Epinastine is combined with Aripiprazole.
Epinephrine
The metabolism of Aripiprazole can be decreased when combined with Epinephrine.
Eplerenone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Eplerenone.
Epoprostenol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Epoprostenol.
Eprosartan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Eprosartan.
Erlotinib
The metabolism of Aripiprazole can be decreased when combined with Erlotinib.
Ertugliflozin
The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Aripiprazole.
Erythromycin
The serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.
Escitalopram
The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Escitalopram.
Esketamine
The risk or severity of hypertension can be increased when Esketamine is combined with Aripiprazole.
Eslicarbazepine acetate
The metabolism of Aripiprazole can be increased when combined with Eslicarbazepine acetate.
Esmolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Esmolol.
Estazolam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Estazolam.
Estradiol acetate
The metabolism of Aripiprazole can be increased when combined with Estradiol acetate.
Estradiol cypionate
The metabolism of Aripiprazole can be increased when combined with Estradiol cypionate.
Estradiol valerate
The metabolism of Aripiprazole can be increased when combined with Estradiol valerate.
Eszopiclone
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Eszopiclone.
Etanercept
The metabolism of Aripiprazole can be increased when combined with Etanercept.
Ethosuximide
The risk or severity of CNS depression can be increased when Ethosuximide is combined with Aripiprazole.
Ethotoin
The metabolism of Aripiprazole can be increased when combined with Ethotoin.
Etomidate
The therapeutic efficacy of Etomidate can be decreased when used in combination with Aripiprazole.
Etoposide
The metabolism of Aripiprazole can be increased when combined with Etoposide.
Etrasimod
The risk or severity of QTc prolongation and torsade de pointes can be increased when Etrasimod is combined with Aripiprazole.
Etravirine
The metabolism of Aripiprazole can be increased when combined with Etravirine.
Everolimus
The metabolism of Aripiprazole can be decreased when combined with Everolimus.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.
Fedratinib
The serum concentration of Aripiprazole can be increased when it is combined with Fedratinib.
Felbamate
The metabolism of Aripiprazole can be increased when combined with Felbamate.
Felodipine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Felodipine.
Fenfluramine
The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Aripiprazole.
Fenoldopam
The risk or severity of adverse effects can be decreased when Fenoldopam is combined with Aripiprazole.
Fentanyl
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fentanyl.
Fexinidazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fexinidazole.
Flibanserin
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Flibanserin.
Fluconazole
The metabolism of Aripiprazole can be decreased when combined with Fluconazole.
Flunisolide
The metabolism of Aripiprazole can be increased when combined with Flunisolide.
Fluocinolone acetonide
The metabolism of Aripiprazole can be increased when combined with Fluocinolone acetonide.
Fluocinonide
The metabolism of Aripiprazole can be increased when combined with Fluocinonide.
Fluoxetine
The serum concentration of Aripiprazole can be increased when it is combined with Fluoxetine.
Fluphenazine
The risk or severity of CNS depression can be increased when Fluphenazine is combined with Aripiprazole.
Flurazepam
The risk or severity of CNS depression can be increased when Flurazepam is combined with Aripiprazole.
Fluticasone propionate
The metabolism of Aripiprazole can be decreased when combined with Fluticasone propionate.
Fluvastatin
The metabolism of Aripiprazole can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Aripiprazole can be decreased when combined with Fluvoxamine.
Formoterol
The therapeutic efficacy of Formoterol can be decreased when used in combination with Aripiprazole.
Fosaprepitant
The metabolism of Aripiprazole can be increased when combined with Fosaprepitant.
Fosinopril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Fosinopril.
Foslevodopa
The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Aripiprazole.
Fosnetupitant
The metabolism of Aripiprazole can be decreased when combined with Fosnetupitant.
Fosphenytoin
The metabolism of Aripiprazole can be increased when combined with Fosphenytoin.
Fostamatinib
The metabolism of Aripiprazole can be decreased when combined with Fostamatinib.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.
Furosemide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Furosemide.
Fusidic acid
The metabolism of Aripiprazole can be decreased when combined with Fusidic acid.
Gabapentin
The risk or severity of CNS depression can be increased when Gabapentin is combined with Aripiprazole.
Gabapentin enacarbil
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Gabapentin enacarbil.
gamma-Hydroxybutyric acid
The risk or severity of CNS depression can be increased when Aripiprazole is combined with gamma-Hydroxybutyric acid.
Ganaxolone
The risk or severity of sedation, somnolence, and CNS depression can be increased when Aripiprazole is combined with Ganaxolone.
Gefitinib
The metabolism of Aripiprazole can be decreased when combined with Gefitinib.
Genistein
The metabolism of Aripiprazole can be increased when combined with Genistein.
Gepirone
The risk or severity of QTc prolongation can be increased when Gepirone is combined with Aripiprazole.
Gepotidacin
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gepotidacin.
Gestodene
The metabolism of Aripiprazole can be decreased when combined with Gestodene.
Givinostat
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Givinostat.
Givosiran
The serum concentration of Aripiprazole can be increased when it is combined with Givosiran.
Glasdegib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Glasdegib.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.
Glofitamab
The serum concentration of Aripiprazole can be increased when it is combined with Glofitamab.
Glucagon
Aripiprazole may increase the gastrointestinal motility reducing activities of Glucagon.
Glyburide
The metabolism of Aripiprazole can be decreased when combined with Glyburide.
Glycerol phenylbutyrate
The serum concentration of Aripiprazole can be increased when it is combined with Glycerol phenylbutyrate.
Golimumab
The metabolism of Aripiprazole can be increased when combined with Golimumab.
Granisetron
The risk or severity of CNS depression can be increased when Granisetron is combined with Aripiprazole.
Griseofulvin
The metabolism of Aripiprazole can be increased when combined with Griseofulvin.
Guanfacine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanfacine.
Haloperidol
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Haloperidol.
Hydralazine
The metabolism of Aripiprazole can be decreased when combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Hydrochlorothiazide.
Hydrocodone
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydrocortisone
The metabolism of Aripiprazole can be increased when combined with Hydrocortisone.
Hydrocortisone acetate
The metabolism of Aripiprazole can be increased when combined with Hydrocortisone acetate.
Hydrocortisone butyrate
The metabolism of Aripiprazole can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone succinate
The metabolism of Aripiprazole can be increased when combined with Hydrocortisone succinate.
Hydroflumethiazide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Hydroflumethiazide.
Hydromorphone
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Hydromorphone.
Hydroxychloroquine
The metabolism of Aripiprazole can be decreased when combined with Hydroxychloroquine.
Hydroxyurea
The metabolism of Aripiprazole can be decreased when combined with Hydroxyurea.
Hyoscyamine
Aripiprazole may increase the anticholinergic activities of Hyoscyamine.
Ibutilide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ibutilide.
Idelalisib
The metabolism of Aripiprazole can be decreased when combined with Idelalisib.
Ifosfamide
The metabolism of Aripiprazole can be increased when combined with Ifosfamide.
Imipramine
The metabolism of Aripiprazole can be decreased when combined with Imipramine.
Indapamide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Indapamide.
Infliximab
The metabolism of Aripiprazole can be increased when combined with Infliximab.
Inotuzumab ozogamicin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Inotuzumab ozogamicin.
Insulin aspart
The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Aripiprazole.
Insulin degludec
The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Aripiprazole.
Insulin detemir
The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Aripiprazole.
Insulin glargine
The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Aripiprazole.
Insulin glulisine
The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Aripiprazole.
Insulin human
The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole.
Insulin lispro
The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Aripiprazole.
Irbesartan
The metabolism of Aripiprazole can be decreased when combined with Irbesartan.
Isavuconazonium
The metabolism of Aripiprazole can be increased when combined with Isavuconazonium.
Isoflurane
The risk or severity of CNS depression can be increased when Isoflurane is combined with Aripiprazole.
Isoniazid
The metabolism of Aripiprazole can be decreased when combined with Isoniazid.
Isoprenaline
The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Aripiprazole.
Isoxsuprine
The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Aripiprazole.
Isradipine
The metabolism of Aripiprazole can be decreased when combined with Isradipine.
Istradefylline
The therapeutic efficacy of Istradefylline can be decreased when used in combination with Aripiprazole.
Ivabradine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ivabradine.
Ivacaftor
The serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Aripiprazole can be increased when combined with Ivosidenib.
Ketamine
The metabolism of Aripiprazole can be increased when combined with Ketamine.
Labetalol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Labetalol.
Lamotrigine
The risk or severity of CNS depression can be increased when Lamotrigine is combined with Aripiprazole.
Landiolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Landiolol.
Lanreotide
The metabolism of Aripiprazole can be decreased when combined with Lanreotide.
Lansoprazole
The metabolism of Aripiprazole can be increased when combined with Lansoprazole.
Lapatinib
The metabolism of Aripiprazole can be decreased when combined with Lapatinib.
Lasmiditan
The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Aripiprazole.
Lemborexant
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Lemborexant.
Letermovir
The metabolism of Aripiprazole can be decreased when combined with Letermovir.
Levamlodipine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Levamlodipine.
Levetiracetam
The risk or severity of CNS depression can be increased when Levetiracetam is combined with Aripiprazole.
Levocetirizine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Levocetirizine.
Levodopa
The absorption of Levodopa can be decreased when combined with Aripiprazole.
Levomilnacipran
The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Levomilnacipran.
Levonordefrin
The therapeutic efficacy of Levonordefrin can be decreased when used in combination with Aripiprazole.
Levorphanol
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Levorphanol.
Levosalbutamol
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Aripiprazole.
Lidocaine
The risk or severity of CNS depression can be increased when Lidocaine is combined with Aripiprazole.
Linagliptin
The metabolism of Aripiprazole can be decreased when combined with Linagliptin.
Linezolid
The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Aripiprazole.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.
Lisdexamfetamine
The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Lisdexamfetamine.
Lisinopril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Lisinopril.
Lithium carbonate
Lithium carbonate may increase the neurotoxic activities of Aripiprazole.
Lithium citrate
Lithium citrate may increase the neurotoxic activities of Aripiprazole.
Lixisenatide
The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Aripiprazole.
Lofexidine
The therapeutic efficacy of Aripiprazole can be increased when used in combination with Lofexidine.
Lomitapide
The metabolism of Aripiprazole can be decreased when combined with Lomitapide.
Lorazepam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Lorazepam.
Lorlatinib
The metabolism of Aripiprazole can be increased when combined with Lorlatinib.
Losartan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Losartan.
Loxapine
The risk or severity of CNS depression can be increased when Loxapine is combined with Aripiprazole.
Lumacaftor
The metabolism of Aripiprazole can be increased when combined with Lumacaftor.
Lumateperone
The risk or severity of adverse effects can be increased when Lumateperone is combined with Aripiprazole.
Lumefantrine
The metabolism of Aripiprazole can be decreased when combined with Lumefantrine.
Lurasidone
Aripiprazole may increase the hypotensive activities of Lurasidone.
Macitentan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Macitentan.
Magnesium sulfate
The therapeutic efficacy of Aripiprazole can be increased when used in combination with Magnesium sulfate.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
Mavacamten
The serum concentration of Aripiprazole can be decreased when it is combined with Mavacamten.
Mecamylamine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Mecamylamine.
Mecasermin
The therapeutic efficacy of Mecasermin can be decreased when used in combination with Aripiprazole.
Meclizine
The risk or severity of CNS depression can be increased when Meclizine is combined with Aripiprazole.
Medroxyprogesterone acetate
The metabolism of Aripiprazole can be increased when combined with Medroxyprogesterone acetate.
Mefloquine
The metabolism of Aripiprazole can be decreased when combined with Mefloquine.
Melatonin
The risk or severity of CNS depression can be increased when Melatonin is combined with Aripiprazole.
Memantine
The therapeutic efficacy of Memantine can be decreased when used in combination with Aripiprazole.
Meperidine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Meperidine.
Mepivacaine
The risk or severity of CNS depression can be increased when Mepivacaine is combined with Aripiprazole.
Meprobamate
The risk or severity of CNS depression can be increased when Meprobamate is combined with Aripiprazole.
Mepyramine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Mepyramine.
Metamfetamine
Metamfetamine may decrease the sedative activities of Aripiprazole.
Metaraminol
The therapeutic efficacy of Metaraminol can be decreased when used in combination with Aripiprazole.
Metaxalone
The risk or severity of CNS depression can be increased when Metaxalone is combined with Aripiprazole.
Methacholine
Aripiprazole may decrease effectiveness of Methacholine as a diagnostic agent.
Methocarbamol
The risk or severity of CNS depression can be increased when Methocarbamol is combined with Aripiprazole.
Methohexital
The risk or severity of CNS depression can be increased when Methohexital is combined with Aripiprazole.
Methsuximide
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Methsuximide.
Methyldopa
The risk or severity of hypotension can be increased when Aripiprazole is combined with Methyldopa.
Methylergometrine
The metabolism of Aripiprazole can be decreased when combined with Methylergometrine.
Methylphenidate
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.
Methylprednisolone
The metabolism of Aripiprazole can be increased when combined with Methylprednisolone.
Metolazone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Metolazone.
Metoprolol
The metabolism of Aripiprazole can be decreased when combined with Metoprolol.
Metronidazole
The metabolism of Aripiprazole can be decreased when combined with Metronidazole.
Metyrapone
The metabolism of Aripiprazole can be increased when combined with Metyrapone.
Metyrosine
Aripiprazole may increase the sedative activities of Metyrosine.
Miconazole
The metabolism of Aripiprazole can be decreased when combined with Miconazole.
Midazolam
The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Aripiprazole.
Midodrine
The therapeutic efficacy of Midodrine can be decreased when used in combination with Aripiprazole.
Mifepristone
The metabolism of Aripiprazole can be increased when combined with Mifepristone.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.
Milnacipran
The metabolism of Aripiprazole can be decreased when combined with Milnacipran.
Minoxidil
The risk or severity of hypotension can be increased when Aripiprazole is combined with Minoxidil.
Mirabegron
The risk or severity of urinary retention can be increased when Aripiprazole is combined with Mirabegron.
Mitapivat
The metabolism of Aripiprazole can be increased when combined with Mitapivat.
Mitotane
The metabolism of Aripiprazole can be increased when combined with Mitotane.
Modafinil
The metabolism of Aripiprazole can be increased when combined with Modafinil.
Moexipril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Moexipril.
Molindone
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Molindone.
Mometasone furoate
The metabolism of Aripiprazole can be increased when combined with Mometasone furoate.
Morphine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Morphine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Nadolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nadolol.
Nafcillin
The metabolism of Aripiprazole can be increased when combined with Nafcillin.
Nalbuphine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nalbuphine.
Naloxegol
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naloxegol.
Naltrexone
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naltrexone.
Naphazoline
The therapeutic efficacy of Naphazoline can be decreased when used in combination with Aripiprazole.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.
Nebivolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nebivolol.
Netupitant
The metabolism of Aripiprazole can be decreased when combined with Netupitant.
Nevirapine
The metabolism of Aripiprazole can be decreased when combined with Nevirapine.
Niacin
The metabolism of Aripiprazole can be decreased when combined with Niacin.
Nicardipine
The metabolism of Aripiprazole can be decreased when combined with Nicardipine.
Nifedipine
The metabolism of Aripiprazole can be increased when combined with Nifedipine.
Nimodipine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nimodipine.
Nisoldipine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nisoldipine.
Nitric Oxide
The metabolism of Aripiprazole can be decreased when combined with Nitric Oxide.
Nitroglycerin
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nitroglycerin.
Nitroprusside
The risk or severity of hypotension can be increased when Aripiprazole is combined with Nitroprusside.
Nitrous oxide
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Nitrous oxide.
Norepinephrine
The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Aripiprazole.
Norgestimate
The metabolism of Aripiprazole can be increased when combined with Norgestimate.
Octreotide
The metabolism of Aripiprazole can be decreased when combined with Octreotide.
Olaparib
The metabolism of Aripiprazole can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Olmesartan.
Olodaterol
The therapeutic efficacy of Olodaterol can be decreased when used in combination with Aripiprazole.
Olutasidenib
The metabolism of Aripiprazole can be increased when combined with Olutasidenib.
Ondansetron
The risk or severity of CNS depression can be increased when Ondansetron is combined with Aripiprazole.
Opicapone
The therapeutic efficacy of Opicapone can be decreased when used in combination with Aripiprazole.
Opium
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.
Orciprenaline
The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Aripiprazole.
Oritavancin
The metabolism of Aripiprazole can be increased when combined with Oritavancin.
Orphenadrine
The serum concentration of Aripiprazole can be increased when it is combined with Orphenadrine.
Osilodrostat
The metabolism of Aripiprazole can be decreased when combined with Osilodrostat.
Ospemifene
The metabolism of Aripiprazole can be decreased when combined with Ospemifene.
Oxaliplatin
The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Aripiprazole.
Oxazepam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Oxazepam.
Oxcarbazepine
The metabolism of Aripiprazole can be increased when combined with Oxcarbazepine.
Oxybuprocaine
The risk or severity of CNS depression can be increased when Oxybuprocaine is combined with Aripiprazole.
Oxybutynin
The metabolism of Aripiprazole can be decreased when combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxycodone.
Oxymetazoline
The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.
Oxymetholone
The metabolism of Aripiprazole can be decreased when combined with Oxymetholone.
Oxymorphone
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxymorphone.
Paclitaxel
The metabolism of Aripiprazole can be increased when combined with Paclitaxel.
Palbociclib
The metabolism of Aripiprazole can be decreased when combined with Palbociclib.
Palonosetron
The risk or severity of CNS depression can be increased when Palonosetron is combined with Aripiprazole.
Palovarotene
The metabolism of Aripiprazole can be increased when combined with Palovarotene.
Pancuronium
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pancuronium.
Panobinostat
The metabolism of Aripiprazole can be decreased when combined with Panobinostat.
Paroxetine
The serum concentration of Aripiprazole can be increased when it is combined with Paroxetine.
Pasireotide
The metabolism of Aripiprazole can be decreased when combined with Pasireotide.
Pazopanib
The metabolism of Aripiprazole can be decreased when combined with Pazopanib.
Peginterferon alfa-2b
The metabolism of Aripiprazole can be decreased when combined with Peginterferon alfa-2b.
Pegvisomant
The metabolism of Aripiprazole can be increased when combined with Pegvisomant.
Pentamidine
The therapeutic efficacy of Pentamidine can be decreased when used in combination with Aripiprazole.
Pentazocine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pentazocine.
Pentobarbital
The metabolism of Aripiprazole can be increased when combined with Pentobarbital.
Peppermint oil
The metabolism of Aripiprazole can be decreased when combined with Peppermint oil.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Pergolide
The risk or severity of adverse effects can be decreased when Pergolide is combined with Aripiprazole.
Perindopril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Perindopril.
Perphenazine
The risk or severity of CNS depression can be increased when Perphenazine is combined with Aripiprazole.
Phendimetrazine
Phendimetrazine may decrease the sedative activities of Aripiprazole.
Phenobarbital
The metabolism of Aripiprazole can be increased when combined with Phenobarbital.
Phenoxybenzamine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Phenoxybenzamine.
Phentermine
Phentermine may decrease the sedative activities of Aripiprazole.
Phentolamine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Phentolamine.
Phenylbutyric acid
The metabolism of Aripiprazole can be decreased when combined with Phenylbutyric acid.
Phenylephrine
The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Aripiprazole.
Phenytoin
The metabolism of Aripiprazole can be increased when combined with Phenytoin.
Pimavanserin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pimavanserin.
Pimozide
The metabolism of Aripiprazole can be decreased when combined with Pimozide.
Pindolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Pindolol.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Aripiprazole.
Piperine
The metabolism of Aripiprazole can be decreased when combined with Piperine.
Polythiazide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Polythiazide.
Pomalidomide
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pomalidomide.
Pralsetinib
The metabolism of Aripiprazole can be increased when combined with Pralsetinib.
Pramipexole
The therapeutic efficacy of Pramipexole can be decreased when used in combination with Aripiprazole.
Pramocaine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pramocaine.
Prasterone
The metabolism of Aripiprazole can be decreased when combined with Prasterone.
Prazosin
The risk or severity of hypotension can be increased when Aripiprazole is combined with Prazosin.
Prednisolone
The metabolism of Aripiprazole can be increased when combined with Prednisolone.
Prednisolone acetate
The metabolism of Aripiprazole can be increased when combined with Prednisolone acetate.
Prednisolone phosphate
The metabolism of Aripiprazole can be increased when combined with Prednisolone phosphate.
Pregabalin
The therapeutic efficacy of Aripiprazole can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of CNS depression can be increased when Prilocaine is combined with Aripiprazole.
Primaquine
The metabolism of Aripiprazole can be decreased when combined with Primaquine.
Primidone
The metabolism of Aripiprazole can be increased when combined with Primidone.
Probenecid
The metabolism of Aripiprazole can be increased when combined with Probenecid.
Prochlorperazine
The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Aripiprazole.
Progesterone
The metabolism of Aripiprazole can be increased when combined with Progesterone.
Proguanil
The metabolism of Aripiprazole can be decreased when combined with Proguanil.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Aripiprazole.
Propafenone
The serum concentration of Aripiprazole can be increased when it is combined with Propafenone.
Propofol
The metabolism of Aripiprazole can be decreased when combined with Propofol.
Propranolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Propranolol.
Propylhexedrine
The therapeutic efficacy of Propylhexedrine can be decreased when used in combination with Aripiprazole.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Aripiprazole.
Pseudoephedrine
Pseudoephedrine may decrease the sedative activities of Aripiprazole.
Pyrantel
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pyrantel.
Quazepam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Quazepam.
Quinapril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Quinapril.
Quinidine
Quinidine may decrease the excretion rate of Aripiprazole which could result in a higher serum level.
Quinine
The metabolism of Aripiprazole can be increased when combined with Quinine.
Quinupristin
The metabolism of Aripiprazole can be decreased when combined with Quinupristin.
Quizartinib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Quizartinib.
Rabeprazole
The metabolism of Aripiprazole can be decreased when combined with Rabeprazole.
Racepinephrine
The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Aripiprazole.
Raloxifene
The metabolism of Aripiprazole can be decreased when combined with Raloxifene.
Ramelteon
The risk or severity of CNS depression can be increased when Ramelteon is combined with Aripiprazole.
Ramipril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Ramipril.
Ranitidine
The metabolism of Aripiprazole can be decreased when combined with Ranitidine.
Ranolazine
The serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.
Regorafenib
The metabolism of Aripiprazole can be decreased when combined with Regorafenib.
Remdesivir
The metabolism of Aripiprazole can be decreased when combined with Remdesivir.
Remifentanil
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Remifentanil.
Remimazolam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Remimazolam.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.
Repotrectinib
The metabolism of Aripiprazole can be increased when combined with Repotrectinib.
Reserpine
The risk or severity of hypotension can be increased when Aripiprazole is combined with Reserpine.
Revumenib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Revumenib.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Aripiprazole.
Rifabutin
The metabolism of Aripiprazole can be increased when combined with Rifabutin.
Rifampin
The metabolism of Aripiprazole can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Aripiprazole can be increased when combined with Rifapentine.
Rifaximin
The metabolism of Aripiprazole can be increased when combined with Rifaximin.
Rilonacept
The metabolism of Aripiprazole can be increased when combined with Rilonacept.
Rilpivirine
The metabolism of Aripiprazole can be decreased when combined with Rilpivirine.
Riluzole
The risk or severity of CNS depression can be increased when Riluzole is combined with Aripiprazole.
Riociguat
The risk or severity of hypotension can be increased when Aripiprazole is combined with Riociguat.
Ritlecitinib
The serum concentration of Aripiprazole can be increased when it is combined with Ritlecitinib.
Ritonavir
The metabolism of Aripiprazole can be decreased when combined with Ritonavir.
Rocuronium
The risk or severity of CNS depression can be increased when Rocuronium is combined with Aripiprazole.
Rolapitant
The metabolism of Aripiprazole can be decreased when combined with Rolapitant.
Romidepsin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Romidepsin.
Ropeginterferon alfa-2b
The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Aripiprazole.
Ropinirole
The therapeutic efficacy of Ropinirole can be decreased when used in combination with Aripiprazole.
Ropivacaine
The risk or severity of CNS depression can be increased when Ropivacaine is combined with Aripiprazole.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.
Rotigotine
Aripiprazole may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Aripiprazole can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Aripiprazole.
Rutin
The metabolism of Aripiprazole can be decreased when combined with Rutin.
Salmeterol
The therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole.
Samidorphan
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Samidorphan.
Sarilumab
The metabolism of Aripiprazole can be increased when combined with Sarilumab.
Satralizumab
The serum concentration of Aripiprazole can be decreased when it is combined with Satralizumab.
Saxagliptin
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.
Scopolamine
The risk or severity of CNS depression can be increased when Scopolamine is combined with Aripiprazole.
Secobarbital
The metabolism of Aripiprazole can be increased when combined with Secobarbital.
Secukinumab
The metabolism of Aripiprazole can be increased when combined with Secukinumab.
Selexipag
The risk or severity of hypotension can be increased when Aripiprazole is combined with Selexipag.
Semaglutide
The therapeutic efficacy of Semaglutide can be decreased when used in combination with Aripiprazole.
Sevoflurane
The risk or severity of CNS depression can be increased when Sevoflurane is combined with Aripiprazole.
Sildenafil
The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Aripiprazole.
Siltuximab
The metabolism of Aripiprazole can be increased when combined with Siltuximab.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.
Sofpironium
Sofpironium may increase the anticholinergic activities of Aripiprazole.
Solriamfetol
The risk or severity of hypertension can be increased when Solriamfetol is combined with Aripiprazole.
Sorafenib
The metabolism of Aripiprazole can be decreased when combined with Sorafenib.
Sotagliflozin
The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Aripiprazole.
Sotatercept
The risk or severity of hypotension can be increased when Aripiprazole is combined with Sotatercept.
Sotorasib
The serum concentration of Aripiprazole can be decreased when it is combined with Sotorasib.
Spironolactone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Spironolactone.
Stiripentol
The metabolism of Aripiprazole can be decreased when combined with Stiripentol.
Succinylcholine
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Aripiprazole.
Sufentanil
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sufentanil.
Sulfadiazine
The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Aripiprazole.
Sulfamethoxazole
The metabolism of Aripiprazole can be decreased when combined with Sulfamethoxazole.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.
Sunitinib
The metabolism of Aripiprazole can be decreased when combined with Sunitinib.
Suvorexant
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Suzetrigine
The metabolism of Aripiprazole can be increased when combined with Suzetrigine.
Tacrolimus
The metabolism of Aripiprazole can be decreased when combined with Tacrolimus.
Tadalafil
The risk or severity of hypotension can be increased when Aripiprazole is combined with Tadalafil.
Taletrectinib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Taletrectinib.
Tamoxifen
The metabolism of Aripiprazole can be increased when combined with Tamoxifen.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Tasimelteon
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Tasimelteon.
Tecovirimat
The metabolism of Aripiprazole can be increased when combined with Tecovirimat.
Tegaserod
The metabolism of Aripiprazole can be decreased when combined with Tegaserod.
Telmisartan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Telmisartan.
Telotristat ethyl
The serum concentration of Aripiprazole can be decreased when it is combined with Telotristat ethyl.
Temazepam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Temazepam.
Teniposide
The metabolism of Aripiprazole can be decreased when combined with Teniposide.
Terazosin
The risk or severity of hypotension can be increased when Aripiprazole is combined with Terazosin.
Terbinafine
The metabolism of Aripiprazole can be increased when combined with Terbinafine.
Terbutaline
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Aripiprazole.
Testosterone
The metabolism of Aripiprazole can be increased when combined with Testosterone.
Testosterone cypionate
The metabolism of Aripiprazole can be increased when combined with Testosterone cypionate.
Testosterone enanthate
The metabolism of Aripiprazole can be increased when combined with Testosterone enanthate.
Testosterone undecanoate
Testosterone undecanoate may increase the hypertensive activities of Aripiprazole.
Tetracaine
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Tetracaine.
Tetracycline
The metabolism of Aripiprazole can be decreased when combined with Tetracycline.
Tetryzoline
The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Aripiprazole.
Thioridazine
The serum concentration of Aripiprazole can be increased when it is combined with Thioridazine.
Thiothixene
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Thiothixene.
Tiagabine
The risk or severity of CNS depression can be increased when Tiagabine is combined with Aripiprazole.
Ticagrelor
The metabolism of Aripiprazole can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Aripiprazole can be decreased when combined with Ticlopidine.
Timolol
The risk or severity of hypotension can be increased when Aripiprazole is combined with Timolol.
Tioconazole
The metabolism of Aripiprazole can be decreased when combined with Tioconazole.
Tirzepatide
The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Aripiprazole.
Tizanidine
The therapeutic efficacy of Tizanidine can be decreased when used in combination with Aripiprazole.
Tocilizumab
The metabolism of Aripiprazole can be increased when combined with Tocilizumab.
Tocopherylquinone
The risk or severity of hypotension can be increased when Aripiprazole is combined with Tocopherylquinone.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.
Tolcapone
The therapeutic efficacy of Tolcapone can be decreased when used in combination with Aripiprazole.
Topiramate
The risk or severity of hyperthermia and oligohydrosis can be increased when Aripiprazole is combined with Topiramate.
Topotecan
The metabolism of Aripiprazole can be decreased when combined with Topotecan.
Torasemide
The risk or severity of hypotension can be increased when Aripiprazole is combined with Torasemide.
Toremifene
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Toremifene.
Tovorafenib
The metabolism of Aripiprazole can be increased when combined with Tovorafenib.
Tramadol
The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Tramadol.
Trandolapril
The risk or severity of hypotension can be increased when Aripiprazole is combined with Trandolapril.
Treosulfan
The metabolism of Aripiprazole can be decreased when combined with Treosulfan.
Treprostinil
The risk or severity of hypotension can be increased when Aripiprazole is combined with Treprostinil.
Triamcinolone
The metabolism of Aripiprazole can be increased when combined with Triamcinolone.
Triazolam
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Triazolam.
Triclabendazole
The metabolism of Aripiprazole can be decreased when combined with Triclabendazole.
Trihexyphenidyl
The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Aripiprazole.
Trimethobenzamide
The risk or severity of CNS depression can be increased when Trimethobenzamide is combined with Aripiprazole.
Triprolidine
The risk or severity of CNS depression can be increased when Triprolidine is combined with Aripiprazole.
Trofinetide
The metabolism of Aripiprazole can be decreased when combined with Trofinetide.
Trospium
The metabolism of Aripiprazole can be decreased when combined with Trospium.
Trovafloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Trovafloxacin.
Tryptophan
The risk or severity of CNS depression can be increased when Tryptophan is combined with Aripiprazole.
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Aripiprazole.
Valproic acid
The metabolism of Aripiprazole can be decreased when combined with Valproic acid.
Valsartan
The risk or severity of hypotension can be increased when Aripiprazole is combined with Valsartan.
Vandetanib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Vandetanib.
Vardenafil
The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Aripiprazole.
Vecuronium
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Vecuronium.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aripiprazole.
Venetoclax
The metabolism of Aripiprazole can be decreased when combined with Venetoclax.
Verapamil
The metabolism of Aripiprazole can be decreased when combined with Verapamil.
Vibegron
The therapeutic efficacy of Vibegron can be decreased when used in combination with Aripiprazole.
Vigabatrin
The risk or severity of CNS depression can be increased when Vigabatrin is combined with Aripiprazole.
Vilanterol
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Vilanterol is combined with Aripiprazole.
Vilazodone
The metabolism of Aripiprazole can be decreased when combined with Vilazodone.
Vinblastine
The metabolism of Aripiprazole can be increased when combined with Vinblastine.
Vinorelbine
The metabolism of Aripiprazole can be decreased when combined with Vinorelbine.
Vitamin E
The metabolism of Aripiprazole can be increased when combined with Vitamin E.
Vorasidenib
The metabolism of Aripiprazole can be increased when combined with Vorasidenib.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Aripiprazole.
Warfarin
The metabolism of Aripiprazole can be increased when combined with Warfarin.
Xylometazoline
The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Aripiprazole.
Zafirlukast
The metabolism of Aripiprazole can be decreased when combined with Zafirlukast.
Zaleplon
The risk or severity of sedation and orthostatic hypotension can be increased when Aripiprazole is combined with Zaleplon.
Zolpidem
Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of CNS depression can be increased when Zonisamide is combined with Aripiprazole.
Zuranolone
The risk or severity of CNS depression can be increased when Zuranolone is combined with Aripiprazole.
Abaloparatide
Aripiprazole may increase the hypotensive activities of Abaloparatide.
Aceclofenac
The risk or severity of hypertension can be increased when Aripiprazole is combined with Aceclofenac.
Acenocoumarol
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acenocoumarol.
Acetylsalicylic acid
The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Aripiprazole.
Acrivastine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Acrivastine.
Adenosine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Adenosine.
Alcaftadine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Alcaftadine.
Amifampridine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Amifampridine.
Amifostine
Aripiprazole may increase the hypotensive activities of Amifostine.
Amiloride
Aripiprazole may increase the hypotensive activities of Amiloride.
Amphotericin B
Aripiprazole may increase the hypotensive activities of Amphotericin B.
Amyl Nitrite
Aripiprazole may increase the hypotensive activities of Amyl Nitrite.
Antipyrine
The risk or severity of hypertension can be increased when Aripiprazole is combined with Antipyrine.
Apixaban
The metabolism of Apixaban can be decreased when combined with Aripiprazole.
Atomoxetine
The risk or severity of hypertension can be increased when Atomoxetine is combined with Aripiprazole.
Atorvastatin
The metabolism of Aripiprazole can be decreased when combined with Atorvastatin.
Atropine
The risk or severity of hypertension can be increased when Atropine is combined with Aripiprazole.
Azithromycin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Azithromycin.
Baclofen
Baclofen may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Balsalazide
The risk or severity of hypertension can be increased when Balsalazide is combined with Aripiprazole.
Belladonna
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Belladonna.
Benzgalantamine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Benzgalantamine.
Besifloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Besifloxacin.
Betaine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Betaine.
Bisacodyl
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aripiprazole.
Bismuth subcarbonate
Aripiprazole may increase the neurotoxic activities of Bismuth subcarbonate.
Bismuth subcitrate potassium
Aripiprazole may increase the neurotoxic activities of Bismuth subcitrate potassium.
Bismuth subgallate
Aripiprazole may increase the neurotoxic activities of Bismuth subgallate.
Bortezomib
The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Aripiprazole.
Bumetanide
Aripiprazole may increase the hypotensive activities of Bumetanide.
Calcium polycarbophil
The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aripiprazole.
Carboxymethylcellulose
The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aripiprazole.
Carteolol
The risk or severity of QTc prolongation can be increased when Carteolol is combined with Aripiprazole.
Castor oil
The therapeutic efficacy of Castor oil can be decreased when used in combination with Aripiprazole.
Cevimeline
The metabolism of Aripiprazole can be decreased when combined with Cevimeline.
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Chlorcyclizine.
Ciclesonide
The metabolism of Ciclesonide can be decreased when combined with Aripiprazole.
Cilostazol
The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Aripiprazole.
Cisplatin
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Cisplatin.
Clindamycin
The metabolism of Aripiprazole can be decreased when combined with Clindamycin.
Clofarabine
Aripiprazole may increase the hypotensive activities of Clofarabine.
Clopidogrel
The metabolism of Aripiprazole can be decreased when combined with Clopidogrel.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Aripiprazole.
Cycloserine
Cycloserine may increase the neurotoxic activities of Aripiprazole.
Dapsone
The metabolism of Aripiprazole can be decreased when combined with Dapsone.
Daridorexant
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Daridorexant.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Aripiprazole.
DaxibotulinumtoxinA
Aripiprazole may increase the neuromuscular blocking activities of DaxibotulinumtoxinA.
Degarelix
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Degarelix.
Desmopressin
The risk or severity of hypertension can be increased when Desmopressin is combined with Aripiprazole.
Diclofenac
The risk or severity of hypertension can be increased when Diclofenac is combined with Aripiprazole.
Diclofenamide
Aripiprazole may increase the hypotensive activities of Diclofenamide.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Aripiprazole.
Didanosine
Didanosine may increase the neurotoxic activities of Aripiprazole.
Diflunisal
The risk or severity of hypertension can be increased when Diflunisal is combined with Aripiprazole.
Digoxin
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Aripiprazole.
Dinutuximab
Aripiprazole may increase the hypotensive activities of Dinutuximab.
Dipotassium phosphate
The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Aripiprazole.
Disulfiram
The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Aripiprazole.
Docusate
The therapeutic efficacy of Docusate can be decreased when used in combination with Aripiprazole.
Dopamine
The risk or severity of hypertension can be increased when Dopamine is combined with Aripiprazole.
Doravirine
The metabolism of Doravirine can be decreased when combined with Aripiprazole.
Doxapram
The risk or severity of hypertension can be increased when Doxapram is combined with Aripiprazole.
Dronedarone
The metabolism of Aripiprazole can be decreased when combined with Dronedarone.
Dutasteride
The risk or severity of hypertension can be increased when Dutasteride is combined with Aripiprazole.
Echothiophate
The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Aripiprazole.
Edrophonium
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Edrophonium.
Elagolix
The metabolism of Elagolix can be decreased when combined with Aripiprazole.
Elexacaftor
The metabolism of Elexacaftor can be decreased when combined with Aripiprazole.
Emedastine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Emedastine.
Eribulin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Eribulin.
Estradiol
The metabolism of Aripiprazole can be decreased when combined with Estradiol.
Etacrynic acid
Aripiprazole may increase the hypotensive activities of Etacrynic acid.
Ethambutol
The metabolism of Aripiprazole can be decreased when combined with Ethambutol.
Ethenzamide
The risk or severity of hypertension can be increased when Aripiprazole is combined with Ethenzamide.
Ethinylestradiol
The metabolism of Aripiprazole can be decreased when combined with Ethinylestradiol.
Etodolac
The risk or severity of hypertension can be increased when Etodolac is combined with Aripiprazole.
Famotidine
The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.
Fenoprofen
The risk or severity of hypertension can be increased when Fenoprofen is combined with Aripiprazole.
Fesoterodine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fesoterodine.
Finasteride
The risk or severity of hypertension can be increased when Finasteride is combined with Aripiprazole.
Flavoxate
The risk or severity of adverse effects can be increased when Flavoxate is combined with Aripiprazole.
Fluorouracil
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fluorouracil.
Flurbiprofen
The risk or severity of hypertension can be increased when Flurbiprofen is combined with Aripiprazole.
Flutamide
The metabolism of Aripiprazole can be decreased when combined with Flutamide.
Fluticasone furoate
The metabolism of Fluticasone furoate can be decreased when combined with Aripiprazole.
Foscarnet
The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Aripiprazole.
Fostemsavir
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fostemsavir.
Frangula purshiana bark
The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Aripiprazole.
Fruquintinib
The metabolism of Fruquintinib can be decreased when combined with Aripiprazole.
Gadobenic acid
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Gadobenic acid.
Galantamine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Galantamine.
Gatifloxacin
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Aripiprazole.
Gemifloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Gemifloxacin.
Ginkgo biloba
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Ginkgo biloba.
Glycerin
The therapeutic efficacy of Glycerin can be decreased when used in combination with Aripiprazole.
Goserelin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin.
Histrelin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Histrelin.
Homatropine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Homatropine.
Homatropine methylbromide
The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Aripiprazole.
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.
Hyaluronidase (human recombinant)
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aripiprazole.
Hyaluronidase (ovine)
The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.
Hydroxyprogesterone caproate
The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Aripiprazole.
Ibandronate
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Aripiprazole.
Ibuprofen
The risk or severity of hypertension can be increased when Ibuprofen is combined with Aripiprazole.
Icosapent
The risk or severity of hypertension can be increased when Icosapent is combined with Aripiprazole.
Idarubicin
The metabolism of Aripiprazole can be decreased when combined with Idarubicin.
Iloprost
Aripiprazole may increase the hypotensive activities of Iloprost.
Imatinib
The serum concentration of Aripiprazole can be increased when it is combined with Imatinib.
Imipenem
Aripiprazole may increase the neurotoxic activities of Imipenem.
Indomethacin
The risk or severity of hypertension can be increased when Indomethacin is combined with Aripiprazole.
Inotersen
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Inotersen.
Ipecac
The metabolism of Ipecac can be decreased when combined with Aripiprazole.
Iptacopan
The metabolism of Iptacopan can be decreased when combined with Aripiprazole.
Irinotecan
The metabolism of Aripiprazole can be decreased when combined with Irinotecan.
Isosorbide dinitrate
Aripiprazole may increase the hypotensive activities of Isosorbide dinitrate.
Isosorbide mononitrate
Aripiprazole may increase the hypotensive activities of Isosorbide mononitrate.
Ketoprofen
The risk or severity of hypertension can be increased when Ketoprofen is combined with Aripiprazole.
Ketorolac
The risk or severity of hypertension can be increased when Ketorolac is combined with Aripiprazole.
Lactitol
The therapeutic efficacy of Lactitol can be decreased when used in combination with Aripiprazole.
Lactulose
The therapeutic efficacy of Lactulose can be decreased when used in combination with Aripiprazole.
Lenvatinib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lenvatinib.
Leuprolide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.
Levocabastine
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Aripiprazole.
Levofloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Levofloxacin.
Levomenthol
The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Aripiprazole.
Levonorgestrel
The metabolism of Aripiprazole can be decreased when combined with Levonorgestrel.
Linaclotide
The therapeutic efficacy of Linaclotide can be decreased when used in combination with Aripiprazole.
Lincomycin
Aripiprazole may increase the neurotoxic activities of Lincomycin.
Lomefloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lomefloxacin.
Loperamide
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Loperamide.
Loratadine
The risk or severity of QTc prolongation can be increased when Loratadine is combined with Aripiprazole.
Lovastatin
The metabolism of Aripiprazole can be decreased when combined with Lovastatin.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Aripiprazole.
Magnesium
The therapeutic efficacy of Magnesium can be decreased when used in combination with Aripiprazole.
Magnesium carbonate
The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aripiprazole.
Magnesium citrate
The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aripiprazole.
Magnesium glycinate
The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aripiprazole.
Magnesium hydroxide
The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aripiprazole.
Magnesium oxide
The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Aripiprazole.
Magnesium salicylate
The risk or severity of hypertension can be increased when Aripiprazole is combined with Magnesium salicylate.
Magnesium trisilicate
The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Aripiprazole.
Malathion
The risk or severity of QTc prolongation can be increased when Malathion is combined with Aripiprazole.
Mannitol
Aripiprazole may increase the hypotensive activities of Mannitol.
Mavorixafor
The risk or severity of QTc prolongation can be increased when Mavorixafor is combined with Aripiprazole.
Mechlorethamine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Mechlorethamine.
Meclofenamic acid
The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Aripiprazole.
Mefenamic acid
The risk or severity of hypertension can be increased when Mefenamic acid is combined with Aripiprazole.
Meloxicam
The risk or severity of hypertension can be increased when Meloxicam is combined with Aripiprazole.
Mesalazine
The risk or severity of hypertension can be increased when Mesalazine is combined with Aripiprazole.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.
Methazolamide
Aripiprazole may increase the hypotensive activities of Methazolamide.
Methscopolamine bromide
The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Aripiprazole.
Methylcellulose
The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Aripiprazole.
Metreleptin
The metabolism of Aripiprazole can be increased when combined with Metreleptin.
Mexiletine
The metabolism of Aripiprazole can be decreased when combined with Mexiletine.
Mineral oil
The therapeutic efficacy of Mineral oil can be decreased when used in combination with Aripiprazole.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Mirtazapine
Aripiprazole may increase the serotonergic activities of Mirtazapine.
Monopotassium phosphate
The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Aripiprazole.
Moxifloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.
Mycophenolate mofetil
The metabolism of Aripiprazole can be decreased when combined with Mycophenolate mofetil.
Nabumetone
The risk or severity of hypertension can be increased when Nabumetone is combined with Aripiprazole.
Naproxen
The risk or severity of hypertension can be increased when Naproxen is combined with Aripiprazole.
Naxitamab
The risk or severity of hypertension can be increased when Aripiprazole is combined with Naxitamab.
Neomycin
Neomycin may increase the neurotoxic activities of Aripiprazole.
Neostigmine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Neostigmine.
Nicotine
The risk or severity of Tachycardia can be increased when Nicotine is combined with Aripiprazole.
Nirogacestat
The metabolism of Nirogacestat can be decreased when combined with Aripiprazole.
Nitrous acid
Aripiprazole may increase the hypotensive activities of Nitrous acid.
Nizatidine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Nizatidine.
Norethisterone
The metabolism of Aripiprazole can be decreased when combined with Norethisterone.
Obinutuzumab
Aripiprazole may increase the hypotensive activities of Obinutuzumab.
Ofloxacin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ofloxacin.
Omaveloxolone
The serum concentration of Aripiprazole can be decreased when it is combined with Omaveloxolone.
Oxaprozin
The risk or severity of hypertension can be increased when Oxaprozin is combined with Aripiprazole.
Oxytocin
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.
Pacritinib
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pacritinib.
Papaverine
Aripiprazole may increase the hypotensive activities of Papaverine.
Parecoxib
The risk or severity of hypertension can be increased when Aripiprazole is combined with Parecoxib.
Paritaprevir
The metabolism of Paritaprevir can be decreased when combined with Aripiprazole.
Perflutren
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Perflutren.
Pheniramine
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pheniramine.
Physostigmine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Physostigmine.
Picosulfuric acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aripiprazole.
Pinaverium
The risk or severity of hypotension can be increased when Aripiprazole is combined with Pinaverium.
Pirfenidone
The metabolism of Pirfenidone can be decreased when combined with Aripiprazole.
Piroxicam
The risk or severity of hypertension can be increased when Piroxicam is combined with Aripiprazole.
Plantago seed
The therapeutic efficacy of Plantago seed can be decreased when used in combination with Aripiprazole.
Plecanatide
The therapeutic efficacy of Plecanatide can be decreased when used in combination with Aripiprazole.
Polyethylene glycol
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aripiprazole.
Polymyxin B
Aripiprazole may increase the neurotoxic activities of Polymyxin B.
Potassium bitartrate
The therapeutic efficacy of Potassium bitartrate can be decreased when used in combination with Aripiprazole.
Potassium chloride
The risk or severity of gastrointestinal ulceration can be increased when Aripiprazole is combined with Potassium chloride.
Potassium sulfate
The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Aripiprazole.
Praziquantel
The metabolism of Aripiprazole can be decreased when combined with Praziquantel.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Aripiprazole.
Propyphenazone
The risk or severity of hypertension can be increased when Aripiprazole is combined with Propyphenazone.
Prucalopride
The therapeutic efficacy of Prucalopride can be decreased when used in combination with Aripiprazole.
Pyridostigmine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pyridostigmine.
Relugolix
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Relugolix.
Revefenacin
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Revefenacin.
Rivaroxaban
The metabolism of Rivaroxaban can be decreased when combined with Aripiprazole.
Rivastigmine
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Rivastigmine.
Sacubitril
Aripiprazole may increase the hypotensive activities of Sacubitril.
Salicylamide
The risk or severity of hypertension can be increased when Aripiprazole is combined with Salicylamide.
Salicylic acid
The risk or severity of hypertension can be increased when Salicylic acid is combined with Aripiprazole.
Salsalate
The risk or severity of hypertension can be increased when Aripiprazole is combined with Salsalate.
Selpercatinib
The risk or severity of hypertension can be increased when Aripiprazole is combined with Selpercatinib.
Selumetinib
The metabolism of Selumetinib can be decreased when combined with Aripiprazole.
Senna leaf
The therapeutic efficacy of Senna leaf can be decreased when used in combination with Aripiprazole.
Sennosides
The therapeutic efficacy of Sennosides can be decreased when used in combination with Aripiprazole.
Serdexmethylphenidate
The risk or severity of hypertension can be increased when Aripiprazole is combined with Serdexmethylphenidate.
Sertraline
The serum concentration of Aripiprazole can be increased when it is combined with Sertraline.
Simvastatin
The metabolism of Aripiprazole can be decreased when combined with Simvastatin.
Siponimod
The risk or severity of hypertension can be increased when Aripiprazole is combined with Siponimod.
Sodium ascorbate
The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Aripiprazole.
Sodium cation
The therapeutic efficacy of Sodium cation can be decreased when used in combination with Aripiprazole.
Sodium citrate
Aripiprazole may increase the neurotoxic activities of Sodium citrate.
Sodium fluorophosphate
The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Aripiprazole.
Sodium phosphate, dibasic
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aripiprazole.
Sodium phosphate, dibasic, unspecified form
The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aripiprazole.
Sodium phosphate, monobasic
The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aripiprazole.
Sodium phosphate, monobasic, unspecified form
The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aripiprazole.
Sodium sulfate
The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Aripiprazole.
Solifenacin
The risk or severity of hypertension can be increased when Aripiprazole is combined with Solifenacin.
Somatrogon
The metabolism of Aripiprazole can be increased when combined with Somatrogon.
Sorbitol
The therapeutic efficacy of Sorbitol can be decreased when used in combination with Aripiprazole.
Stavudine
Stavudine may increase the neurotoxic activities of Aripiprazole.
Sulfasalazine
The risk or severity of hypertension can be increased when Sulfasalazine is combined with Aripiprazole.
Sulfate ion
The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aripiprazole.
Sulindac
The risk or severity of hypertension can be increased when Sulindac is combined with Aripiprazole.
Tafenoquine
The metabolism of Tafenoquine can be decreased when combined with Aripiprazole.
Telavancin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Telavancin.
Terlipressin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Terlipressin.
Tezacaftor
The metabolism of Tezacaftor can be decreased when combined with Aripiprazole.
Thiotepa
The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Thiotepa.
Thonzylamine
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Thonzylamine.
Tolmetin
The risk or severity of hypertension can be increased when Tolmetin is combined with Aripiprazole.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Aripiprazole.
Triamterene
Aripiprazole may increase the hypotensive activities of Triamterene.
Triptorelin
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Triptorelin.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Aripiprazole.
Vadadustat
The serum concentration of Aripiprazole can be increased when it is combined with Vadadustat.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Aripiprazole.
Valdecoxib
The risk or severity of hypertension can be increased when Valdecoxib is combined with Aripiprazole.
Venlafaxine
The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Venlafaxine.
Vericiguat
Aripiprazole may increase the hypotensive activities of Vericiguat.
Viloxazine
The metabolism of Aripiprazole can be decreased when combined with Viloxazine.
Vonoprazan
The metabolism of Vonoprazan can be decreased when combined with Aripiprazole.
Vorinostat
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Vorinostat.
Xanomeline
The metabolism of Xanomeline can be decreased when combined with Aripiprazole.
Ziconotide
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Ziconotide.